Management of Refractory Secretions in Dying Patients

Introduction to Glycopyrrolate

The National Comprehensive Cancer Network recommends glycopyrrolate as a first-line option for managing excessive secretions, administered at 0.2-0.4 mg IV or subcutaneous every 4 hours as needed, due to its unique pharmacologic profile and minimal CNS effects 1, 2, 3
Glycopyrrolate does not effectively cross the blood-brain barrier, making it significantly less likely to cause sedation, drowsiness, confusion, or delirium compared to other anticholinergics, which is a critical advantage in end-of-life care 1, 2

Glycopyrrolate should be administered via IV or subcutaneous route every 4 hours as needed, with a dose of 0.2-0.4 mg per dose, and has a more rapid onset compared to transdermal patches 1, 2, 3
The expected side effects of glycopyrrolate include peripheral anticholinergic effects such as dry mouth and urinary retention, but minimal CNS effects 1, 2

If glycopyrrolate fails, octreotide 100-200 mcg subcutaneous every 8 hours should be considered as it works through a different mechanism, reducing secretions by decreasing gastrointestinal and respiratory secretion production 2, 4
If glycopyrrolate is unavailable, atropine 1% ophthalmic solution 1-2 drops sublingually every 4 hours represents an alternative route of administration that may be more effective than other atropine formulations 1, 3

It is essential to monitor for urinary retention and constipation as peripheral anticholinergic effects of glycopyrrolate, though these are generally less concerning than CNS effects in dying patients 1, 2
Avoid combining multiple anticholinergics simultaneously as this increases delirium risk without improving efficacy 5